Prise en charge des CBNPC oligométastatiques synchrones

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Nieder, 2014, Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers?, Med Princ Pract, 23, 526, 10.1159/000365634 Eberhardt, 2015, The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer, J Thorac Oncol, 10, 1515, 10.1097/JTO.0000000000000673 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Dingemans, 2019, Definition of synchronous oligometastatic Non-Small Cell Lung Cancer – a consensus report, J Thorac Oncol, 14, 2109, 10.1016/j.jtho.2019.07.025 Lievens, 2020, Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document, Radiother Oncol, 148, 157, 10.1016/j.radonc.2020.04.003 Merino Lara, 2018, Multisite stereotactic body radiotherapy for meta static non-small-cell lung cancer: delaying the need to start or change systemic therapy?, Lung Cancer, 124, 219, 10.1016/j.lungcan.2018.08.005 Downey, 2002, A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis, Lung Cancer, 38, 193, 10.1016/S0169-5002(02)00183-6 Collen, 2014, Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, 25, 1954, 10.1093/annonc/mdu370 De Ruysscher, 2018, Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450), J Thorac Oncol, 13, 1958, 10.1016/j.jtho.2018.07.098 Xu, 2018, Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs, J Thorac Oncol, 13, 1383, 10.1016/j.jtho.2018.05.019 Wang, 2022, Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated Non-Small Cell Lung Cancer, J Natl Cancer Inst Baulm, 2019, Pembrolizumab after completion of locally ablative therapy for oligometastatic Non-Small Cell Lung Cancer: a phase 2 trial, JAMA Oncol, 5, 1283, 10.1001/jamaoncol.2019.1449 Gomez, 2019, Local consolidative therapy vs. maintenance therapy observation for patients with oligometa static non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Iyengar, 2018, Consolidative radiotherapy for limited metastatic Non-Small-Cell Lung Cancer: a phase 2 randomized clinical trial, JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501 Wu, 2022, Local consolidative therapy versus systemic therapy alone for meta-static non-small cell lung cancer: a systematic review and meta-analysis, Int J Radiat Oncol Biol Phys, 114, 635, 10.1016/j.ijrobp.2022.02.023 Shaverdian, 2017, Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of Non-Small-cell Lung Cancer: a secondary analysis of the KEYNOTE-001 phase 1 Trial, Lancet, 7, 895, 10.1016/S1470-2045(17)30380-7 Theelen, 2019, Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced Non-Small Cell Lung Cancer: results of the PEMBRO-RT phase 2 randomized clinical trial, JAMA Oncol, 5, 1276, 10.1001/jamaoncol.2019.1478 Theelen, 2021, Pembrolizumab with or without radio therapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Respir Med, 9, 467, 10.1016/S2213-2600(20)30391-X Berzenji, 2021, The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review, Transl Lung Cancer Res, 10, 3409, 10.21037/tlcr-21-58 David, 2017, A model to predict the use of surgical resection for advanced-stage non-small cell lung cancer patients, Ann Thorac Surg, 104, 1665, 10.1016/j.athoracsur.2017.05.071 Lehrer, 2021, Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis, JAMA Oncol, 7, 92, 10.1001/jamaoncol.2020.6146 Ruers, 2017, Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial, J Natl Cancer Inst, 109, 1, 10.1093/jnci/djx015 Petrelli, 2018, Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta-analysis, Lung Cancer, 126, 194, 10.1016/j.lungcan.2018.11.017 Mahajan, 2017, Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial, Lancet Oncol, 18, 1040, 10.1016/S1470-2045(17)30414-X Aoyama, 2006, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 295, 2483, 10.1001/jama.295.21.2483 Chang, 2009, Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, Lancet Oncol, 10, 1037, 10.1016/S1470-2045(09)70263-3 Chen, 2020, Stereotactic body radiotherapy of adrenal meta stases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients, Int J Radiat Oncol Biol Phys, 107, 48, 10.1016/j.ijrobp.2020.01.017 Mahadevan, 2018, Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® patient registry, Radiat Oncol, 13, 26, 10.1186/s13014-018-0969-2 Rusthoven, 2009, Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases, J Clin Oncol, 27, 1579, 10.1200/JCO.2008.19.6386 Lodeweges, 2017, Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases, J Thorac Oncol., 12, 1442, 10.1016/j.jtho.2017.05.015 Huo, 2017, Stereotactic spine radiosurgery: review of safety and efficacy with respect to dose and fractionation, Surg Neurol Int, 8, 30, 10.4103/2152-7806.200581 Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic Non-Small-Cell Lung Cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003 Li, 2018, Prognostic factors of oligometa-static non-small cell lung cancer: a meta-analysis, J Thorac Dis, 10, 3701, 10.21037/jtd.2018.05.105 Miyawaki, 2021, Proposing synchronous oligometastatic Non-Small-Cell Lung Cancer based on progression after first-line systemic therapy, Cancer Sci, 112, 359, 10.1111/cas.14707 Tönnies, 2014, Metastasectomy for synchronous solitary Non-Small Cell Lung Cancer metastases, Ann Thorac Surg, 98, 249, 10.1016/j.athoracsur.2014.03.028 Frost, 2018, Local ablative treatment for synchronous single organ oligometastatic lung cancer – a propensity score analysis of 180 patients, Lung Cancer, 125, 164, 10.1016/j.lungcan.2018.09.021 Kroeze, 2023, Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium, Lancet Oncol, 24, e121, 10.1016/S1470-2045(22)00752-5 Iyengar, 2023, Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline, Pract Radiat Oncol, 10.1016/j.prro.2023.04.004 Lussier, 2011, MicroRNA expression characterizes oligometastasis(es), PLoS One, 6, e28650, 10.1371/journal.pone.0028650 Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis, Nat Commun., 9, 1793, 10.1038/s41467-018-04278-6 Videtic, 2023, Local treatments of oligometastatic and oligoprogressive NSCLC should become the standard of care, J Thorac Oncol, 18, 986, 10.1016/j.jtho.2023.05.003 Macbeth, 2023, Local treatments of oligometastatic and oligoprogressive NSCLC should not become the standard of care, J Thorac Oncol, 18, 981, 10.1016/j.jtho.2022.09.227